A preliminary study of pharmacogenetic biomarkers for individuals with autism and gastrointestinal dysfunction

ConclusionsFurther research is warranted to reveal the potential use of CYP2C9 and SLC6A2 SNP expression as pharmacogenetic biomarkers to determine the most appropriate medication for individuals with autism and/or GI dysfunction.
Source: Research in Autism Spectrum Disorders - Category: Psychiatry Source Type: research